Target intelligence / Profile preview

WD repeat domain 70 (WDR70)

Target
WDR70
Molecular classification
WD40 repeat protein, Chromatin regulator, Protein interaction scaffold, Subunit of Cullin-RING ubiquitin ligase (CRL4) complex
01

Overview

WD repeat domain 70 is a scaffold protein composed of six WD40 repeat domains that assemble into multiprotein complexes critical for DNA double-strand break repair. It functions as a subunit of the CRL4 complex and interacts with RNF20/40 E3 ligases to mediate monoubiquitylation of histone H2B, thereby enabling recruitment and transcription of major homology-directed repair genes such as BRCA1, BRCA2, and RAD51[2][1]. Loss or mutation of WDR70 impairs DNA repair, leading to genomic instability and increased susceptibility to carcinogenesis, especially in colorectal cancer[2]. There is growing interest in targeting WDR70 for therapeutic intervention in cancer, yet direct, clinically-approved drugs are not currently available[3].

Other names
WD40 repeat-containing protein 70WDR70
02

Mechanism of action

Drug targeting would likely act by: - Modulating protein-protein interactions within DNA repair or chromatin complexes - Affecting E3 ligase-mediated histone ubiquitylation - Altering transcriptional regulation of key DNA repair genes (BRCA1, BRCA2, RAD51)

03

Biological functions

DNA repair (homology-directed repair, non-homologous end-joining)Transcription regulationChromatin remodeling via histone H2B monoubiquitylationCoordination of multi-protein complex assemblyMaintenance of genome stability
04

Disease associations

Cancer (especially colorectal cancer, due to its role in DNA repair and genomic integrity)Defective DNA repair syndromes
05

Safety considerations

Targeting WDR70 or its associated complexes could compromise genome stability and cell viabilityInhibition may sensitize normal cells to DNA damage, raising toxicity concerns
06

Interacting drugs

No approved or clinical-stage drugs directly targeting WDR70 are reported, but modulation of its activity affects sensitivity to DNA repair pathway inhibitors (e.g., ATR inhibitor, PARP inhibitor)
07

Biomarkers

Reduced WDR70 expression or dysfunction is associated with defective DNA damage signaling (γH2AX, phosphorylated RPA2, ATR/CHK1 activation)Mutations (e.g., in interaction partners like CHRAC1 D121Y) in colorectal cancer impacting DNA repair efficiency

Beyond the preview

Go deeper on WD repeat domain 70 (WDR70).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD repeat domain 70 (WDR70).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call